Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary
March 5, 2024
Earnings Call Speaker Segments
Michael Preuss
executiveHi, everyone, and thank you so much for being with us today for our strategic update and the 2024 annual press conference. We really appreciate your time and your interest in Bayer. As you're aware, later today here in London we'll be hosting our Capital Markets Day with investors and analysts. Ahead of that afternoon session, we wanted to give you a chance to hear an update on the company's strategic priorities and outlook, along with business results for 2023 and guidance for 2024. Every member of Bayer's Board of Management is here in the room, and you'll be hearing from each of them before we open the floor for your questions and their answers. Okay, let's get going. Before we start, I'd like to point out the forward-looking statement disclaimer and the other legal information shown on this chart. With that, I'd now like to hand things over to Bayer's CEO, Bill Anderson.
Bill Anderson
executiveOkay, hello everybody, and thank you for being with us today. As Michael mentioned a moment ago, our entire board is present, and that includes the two members who joined most recently. Heike came on board last summer, so some of you may already know her. Julio is so recent an addition that he isn't officially on board at this point. He was appointed to become the next president of our Consumer Health division. Julio brings 30 years in healthcare, and he combines robust commercial, financial, and analytic skill sets. He arrives from the Pharma division, and he has likewise spent a substantial amount of time in Consumer Health. Heiko remains fully on board through the end of April, and he will represent his business today. But I'd also like to offer you the opportunity to become acquainted with Julio, so why don't you share a few words?
Julio Triana
executiveYes, thank you, Bill, and greetings to everyone. Being here today genuinely makes me happy. I can’t wait to formally become part of the board and the Consumer Health team. Consumer Health is a remarkably appealing and fast-moving market. Great brands and outstanding science are what our business is built on. Heiko and the team have accomplished wonderful things with this business, and I’m eager to begin and to get acquainted with all of you. Thank you. Thanks, Bill.
Bill Anderson
executiveThanks, Julio. We truly appreciate everyone taking an interest in Bayer. It's a real pleasure to have this chance to walk all of you through our plans for the company today. I'll begin with a look at where the company has come from. Bayer has built up businesses in Crop Science, Pharmaceuticals, and Consumer Health over many decades. That came about through organic growth as well as a great deal of M&A, among which were 12 major transactions in under 20 years — seven acquisitions and five separations. During that period, Bayer has shifted its lines of business almost entirely, from ranking among the biggest chemical companies in the world to now having three areas of focus. That is a remarkable feat, and my predecessors demonstrated remarkable strategic foresight and guts. Yet all of that rearrangement has carried a very high cost, both regarding the debt now sitting on our balance sheet and in pulling attention away from operations. What do I mean by operations? It's really the core task of making sure each employee can add value for customers every day. So that's where we come from. Today we're only 10 weeks into the year, but I'd like to give you a snapshot of what has happened, both within and beyond the company, in just the past 65 days.
Bill Anderson
executiveOn the Pharma side, we obtained market authorization for EYLEA 8 mg in the EU. Elinzanetant, our experimental medicine for menopause symptoms, hit every primary and secondary endpoint across two phase III studies. We announced that we have both the plan and the backing of our employee representatives to put our new operating model in place. That matters because this is a massive change. To tackle our debt challenge, we proposed reducing the dividend to the legal minimum. That step is unprecedented in Bayer's modern history. We received an adverse verdict in glyphosate litigation, we won another case, and a third ended in a mistrial. Right now, we're bringing short stature corn to farmers in the U.S. Yesterday, we bolstered our Pharma pipeline with a new cardiology drug for Europe. And tomorrow, Aspirin marks its 125th birthday. We recently launched two new formulations behind the brand in both the U.S. and Germany. Think about that — a 12-decade heritage, and we're still innovating behind it. Meanwhile, across these 10 weeks, our share price has hovered around a 20-year low. Well, I share this 65-day retrospective because it's indicative of what I found when I joined the company: a relevant mission, strong scientific and innovative capacity, a Pharma business that's progressing very well on an important rebuild.
Bill Anderson
executiveWe hold leading positions in Crop Science and Consumer Health, and our workforce is highly skilled and dedicated. That said, some material challenges remain unresolved, and they weigh on the company — and it's time for that to change. Seizing our opportunities while solving our challenges: that's what today is about. We have to think about what's best for Bayer today so the company can have a better future tomorrow. Let me show this idea through a personal experience. In 2021, I had several important plans and goals, professional and personal alike. But on a Sunday morning that June, I was skateboarding — something I'd done regularly for more than 40 years — and I had a freak fall, and I broke my right femur in 4 places. I was face down in the street, with no friends or family with me, and my leg was bent almost 90 degrees, and the pain had me on the edge of unconsciousness. In that moment, every plan and goal of mine was suspended. Facts took over. I needed a hospital, a surgeon, titanium parts to hold my bone together, days of nursing care, and months of intense physical therapy.
Bill Anderson
executiveOkay, so today I can stand in front of you able to do all the things I could do prior to my accident — with one exception: skateboarding, because my wife hasn't given me the authorization for that. My changed circumstances didn't halt my chase of the most important goals, but they did push me to change my path. Before the accident, I was a man with a plan. After it, I was a man with a plan and a shattered femur. A broken leg didn't turn me into a lesser person, but it did control what I did right away, and it sharply narrowed my options at that moment. Thanks to the wonders of modern video conferencing, I hardly missed a single day of work, yet the accident pretty much reshaped my ability to do everything else. There are certain parallels between my personal story and Bayer today. Today, we're a company that delivers a tremendous impact across the world each day for millions of farmers, patients, and consumers. Sustainability is an integral piece of our operations, and our businesses contribute enormously to food security, to health equity, and to the health of the planet. We've demonstrated that we can lead in industries. We've demonstrated that we can turn businesses around.
Bill Anderson
executiveWe also possess a track record spanning many decades when it comes to overseeing our portfolio, putting money into businesses we intend to grow, and parting ways with operations that are better positioned somewhere else. If I were to halt the description of Bayer at that point, several strategic questions about the firm could be raised. What structure suits the company best? Do all of these businesses sit optimally beneath a single roof? Are there fresh business areas adjacent to the current ones—or even farther out—that we ought to be pursuing? Yet the description of Bayer does not halt there. We are a life science company driven by mission with high impact and three strong businesses, but in four places we are badly broken. Shareholders who have stayed with us over the past five years have felt the pain of this condition, and our employees have endured multiple rounds of layoffs. All of that has been highly unsatisfactory, since the brokenness has not been repaired. The four broken areas consist of our Pharma loss of exclusivities, litigation, our debt levels, and a hierarchical bureaucracy that blocks progress. These four challenges sharply constrain our capacity to choose our destiny, whether as a three-division company or in smaller parts. We gave serious consideration to the structure of our company. We did so with assistance from numerous external advisors and a set of assessment criteria encompassing valuation levels, value creation, speed of execution, execution certainty, timing of cash generation, and the resulting leverage ratios, plus the impact on our future optionality.
Bill Anderson
executiveOn the surface, there are genuinely sound reasons for making a change. In our industries, a pure-play structure has turned into the standard. It is definitely the most straightforward route. Its attractiveness, I believe, is something we can all grasp. Yet you must always weigh where you are starting from, and as things stand, those four troubled areas drastically restrict the structural choices available to us. Let me explain what I mean. An IPO or a spin would demand a company-wide effort spanning 18 to 24 months, and cash contributions would be pushed back past that window. During that period, leverage ratios at RemainCo or NewCo might rise substantially, which could put reasonable financing access at risk. A sale is another option worth examining, though for us it only matters for Consumer Health. And that, you know, might prove appealing. What I mean is, the one-time proceeds could let us retire some debt. Consumer Health is an excellent business. It has a history of posting outstanding results. A separation, however, would carry meaningful costs and tax leakage. Comparables also give us fairly clear signals that valuations are weak right now, and we would be saying farewell to a business that produces dependable cash annually.
Bill Anderson
executiveBeyond that, neither path resolves the uncertainty around litigation or the expiration of exclusivities in Pharma. I've observed firms attempt to survive patent cliffs through the acquisition of phase III assets. That approach is extremely costly and carries substantial risk, and honestly, the sector's record with such transactions is weak. Lastly, whatever form of structural change would absorb most of management's time and energy across a minimum of a 24-month span. Since I came to Bayer, I've spoken with numerous CEOs who have been through major structural overhauls. Their message to me was unambiguous: you can revamp operations to lift performance, or you can undertake a major structural change, but doing both simultaneously isn't possible. A major structural change might justify everyone fully engaged... But not at this moment, when we require complete focus on surmounting these four challenges. In brief, regarding the structure question, our response is not now, and that must not be misread as never. Naturally, we'll remain open-minded. That's always our stance, yet our priority is on addressing our challenges, improving performance, and building strategic flexibility. We're confident this path is the best one for Bayer.
Bill Anderson
executiveSo over the coming 24 to 36 months, that is where our energy and focus will go: putting our dynamic shared ownership operating model into practice to lift performance, deal with litigation in a meaningful way, move the debt level toward an A rating, and build a strong Pharma pipeline. The last 11 months were not simply a period of analysis. During that stretch, we have acted boldly. In the summer of 2023, we launched a decisive overhaul of Bayer's operating model, which has already brought faster decision-making, quicker innovation timelines, and simpler structures. We have mobilized the whole company, employee representatives included, behind a reimagining of every facet of how we operate. In July of 2023, we made the tough call to cut our guidance. In August, a few weeks later, I said we had to deliver to begin learning, earning back trust. In November, I said we were confident in our adjusted guidance. Today, as you saw from the results we published this morning, we delivered at the upper end of each aspect of our adjusted guidance. Now, there are 12 more ninety-day cycles between today and the end of 2026. At each one of those, our team, we intend to get up and say that we've delivered.
Bill Anderson
executiveThe Bayer Supervisory Board is undertaking significant changes as well, which includes bringing in fresh members who bring know-how in capital markets, mass litigation, and Pharma product development. A new incentive compensation system is also being proposed by them for us and for Bayer's managers. Over the short term, three straightforward measures will determine how our management team is compensated: revenue growth, profitability, and cash. That triangle is what we'll be measured on, and the measurement will happen for us as a team rather than as individuals. Over the long term, and drawing heavily on input from shareholders, the Supervisory Board is putting forward a compensation scheme that ties management outcomes more tightly to what shareholders experience. Quite a lot of change is underway at Bayer. It's making us more accountable and transparent. That begins with a hard look at our four challenges. The first one is the Pharma loss of exclusivities along with our pipeline. We regard this as the biggest lever for recovering value for the company. I'm pleased with the progress here, but much more remains to be done. A strong early pipeline has been developed by the company, and we hold some very promising later-stage candidates, yet there's no doubt that difficult years lie ahead as Xarelto and EYLEA confront a loss of exclusivity. Our team is focused with unwavering attention on building the base business, accelerating our highest impact early-stage projects, and maximizing the momentum already behind our launch assets.
Bill Anderson
executiveIn 2023, we filed eight investigational new drug applications, and we intend to maintain that cadence. Our priority is to grow the worth of our assets as time goes on, and we're relying on our new operating model to sharpen how quickly and efficiently we do that work. Litigation is another significant hurdle. It places an enormous strain on our finances and equally on our capacity to put money into better medicines and solutions for feeding the world. Right now, both PCBs and glyphosate sit at the top of the boards and my agenda. These are quite distinct cases with differing dynamics, which influences the character and speed of how we respond. But I can say this: we are implementing a number of changes to the way we handle them. Let me begin briefly with PCBs. Monsanto ceased selling this product back in the 1970s, and numerous, numerous parties were part of the production chain, so we are not on our own. This dynamic differs from glyphosate. PCB litigation will rise and fall as time passes, and that will shape our response. We will defend ourselves in individual cases while we also evaluate the wider situation. Turning to glyphosate, let me begin with some facts.
Bill Anderson
executiveGlyphosate is safe. Regulatory agencies and scientific organizations around the globe have confirmed that repeatedly. Only 3 months ago, the European Commission renewed the product's registration for a further 10 years, acting on the European Food Safety Authority's comprehensive review. Even in California — a state where I've resided for many years, and where ordinary household products come with cancer warnings — a court ruled that attaching a cancer warning label to glyphosate products would be false and misleading. Glyphosate is essential. It ranks as the most widely used crop protection chemical globally, thanks to the distinctive part it plays in holding weeds back and safeguarding yields of key crops, ranging from row crops to fruits and vegetables... This carries big consequences for food prices staying affordable, which matters especially now, following several years of elevated food inflation. Glyphosate makes no-till farming possible, and that is pivotal for retaining carbon in the soil, which substantially cuts both energy and fertilizer needs. Absent glyphosate, farming's carbon emissions would climb dramatically. Glyphosate is a major factor in farm economics. Risks to its availability put farmers' livelihoods in jeopardy, as shown by the over 360 farmer advocacy groups that recently raised this matter with the U.S.
Bill Anderson
executiveCongress. They're worried since Bayer is the sole American supplier of glyphosate. Those are the facts. Now, turning to actions. We have several cases coming up this year. Our new general counsel has engaged some new outside counsel, and we're adding a litigation expert to our Supervisory Board. We will defend ourselves vigorously. We welcome positive outcomes such as those we saw on Friday, and we will keep appealing every unfavorable verdict. By the way, we continue to see awards reduced by roughly 90% on average, and we're still working to get these verdicts set aside completely. It's clear that a defense-only strategy is not enough. We're examining the litigation topic from every angle, inside and outside the courtroom. That includes much more thorough engagement with other stakeholders in the public policy realm. It includes considering every possible means to bring closure to these lawsuits for the company and for our customers. You should expect more action from Bayer in this space, but we'll only comment on it when and where it's in the company's best interests. Third, the debt. You can expect an intense focus on profitable growth from our base business, as well as conversion to higher cash flows, and we're not stopping there.
Bill Anderson
executiveA couple of weeks back, we laid out what we intend to do with the dividend policy so that we can bring debt down. Over the coming 3 years, our plan is to distribute just the legally required minimum. Taking that route was not easy. Indeed, never before in Bayer's post-war history has the company made a call like this. We are set on regaining strategic optionality, and we'll keep making the tough choices that serve the company's interests. Our confidence is high that shareholders will approve the proposal when they meet at the upcoming shareholders meeting. From the reactions I have heard and seen, it's really clear that this hard step was unavoidable. With the cash we retain, bringing debt down will come first. This move will help us move toward a single A rating category across the next 36 months. Last, bureaucracy. We're already well along in rolling out a radical new operating model, Dynamic Shared Ownership. Under this system, the whole company is redesigned into teams whose focus is improving customers' lives or bettering our products, and everything else gets eliminated. To be clear, this isn't merely a program for saving costs. Savings will be the outcome, not the goal. Through customer proximity and innovation, DSO will fuel growth.
Bill Anderson
executiveConsumer Health is the division where innovation cycles move fastest, and it has already cut down timelines for a number of key launches. In Crop Science, we're rethinking the commercial model so the customer experience is simpler across all four regions, while Pharma is speeding up market access for EYLEA 8 mg, one of our biggest launches this year. That kind of work is exactly why I feel confident, because beyond the four challenges I just talked about, there's plenty in our businesses to build on. Dynamic Shared Ownership will get the whole organization focused on customers and products. Resources will move dynamically — away from the old static processes, the committees and governance — and toward our highest impact projects. As of 2026, it will remove about EUR 2 billion in annual organizational costs, but costs are just one of the benefits. Now, I'll hand things over to Heike to explain more about how we're bringing DSO to life.
Heike Prinz
executiveThank you, Bill. By the close of this year, Dynamic Shared Ownership is going to reach every single area of our company, with committed teams built around customers and products and concentrated on them. A network of enabling and technical functions backs these teams, which allows decisions to be made more quickly and in the ways that serve customer needs best, more synergistically than our old hierarchical setup allowed. At the close of 2023, we already had 50 teams and 2,500 people operating under this model. As of today, we have expanded that to 300 teams, with thousands more working inside the system, and we will keep scaling at a speed never seen before, and we expect nearly every Bayer employee to be engaged in DSO come year-end. To achieve that, we are undertaking a full redesign of how we operate. We are cutting layers down to the bare minimum conceivable. In certain areas today, there are 12 layers separating Bill from our customers. So in this regard, our goal is 5 to 6 layers throughout the whole company... We are also rethinking span of enablement and coaching — what we previously referred to as span of control — aiming for a minimum of more than 15 employees per leader, and we are optimizing the structures of our management.
Heike Prinz
executiveTo give you a sense of scale, right now we’ve got over 17,000 people managers. Over 30% of them are in charge of small micro teams with few reports — 4 or fewer direct reports. A few managers have just one direct report. That doesn’t just add complexity; it highlights the basic problems with a hierarchical model. So across our businesses, we’re really flipping the script. Here’s one concrete example from our Pharma team in North America. At the end of last year, they went live with a completely new operating model. They cut manager headcount by roughly 40%, and they raised the span of coaching from 8 to 9 employees per leader to 15 to 20. They now run with 68 field-based so-called micro enterprises, built to deliver a unified, far more seamless customer experience. These squads of roughly 15 to 20 people are mostly autonomous, cross-functional units that set their own strategy and execute it. They own their spend and can flex resources or change team composition to respond to unique market dynamics and opportunities. That has already produced radical changes that unleash the power in our organization, with a much flatter organization, with more people coached and guided by far fewer leaders.
Heike Prinz
executiveLooking at our enabling functions, we're seeing significant shifts as well. There are two major moves worth calling out that we've made toward a setup where customers—rather than internal processes—sit at the center. We're dissolving entire organizations, like our in-house business consulting team, and we're cutting back control organizations substantially—our internal audit team, for instance, by close to 50%, shrinking its scope so it focuses only on material risks. In every one of our functions, everything is on the table. We aren't falling back on how things have always been done; instead, we're genuinely examining what's actually needed, what truly adds value, and how we can best position ourselves to meet customer needs. As a labor director, I'd be remiss if I failed to note how crucial our employee representatives are throughout this transformation. Under a Co-determination system like Germany's, changes of the magnitude we're undertaking can sometimes take more time. Luckily, our employee representatives grasp the urgency of our situation and are highly supportive partners in this transformation. They're helping us move swiftly and at the pace we need in order to succeed. I'm in regular contact with them, and we're confident that DSO will propel Bayer to a better performance while creating more meaningful jobs at our company.
Heike Prinz
executiveWith that said, I'll pass things back over to Bill.
Bill Anderson
executiveThanks, Heike. Yeah, it's been wonderful having you with us over these past months, and there's genuinely important work ahead of us, and we're quite lucky to have someone with your abilities and expertise on the case. So in a moment, Wolfgang will explain how we expect our business to develop in 2024. But first, I want to give you a picture of where we're taking Bayer across the next three years. By the end of 2026, I see a company that has come through the loss of exclusivities and rebuilt the Pharma pipeline, that pushed forward effective strategies to contain litigation and has meaningfully strengthened our leverage ratios, that has reinforced our leading position in agriculture, and that is well on its way to bringing 10 blockbusters to market in Crop Science, and that is outperforming our peers with leading brands in Consumer Health. I see a Bayer that has dealt with the bureaucracy, fully centered on customers and products, with every one of our businesses leaner and more effective than their competitors, with the strategic flexibility to claim its own destiny and a performance system that pushes us to be better at rapid intervals. The reason for all of that, why it's so important, is because the work we do truly matters.
Bill Anderson
executiveWhen we talk about "Health for all, hunger for none," that isn't us being naive idealists. Hunger and disease are not issues that can be solved even over a lifetime. They rank among the biggest problems the world faces right now, and we believe our businesses can serve as a genuine force in tackling them. In Crop Science, that translates to taking agricultural output at today's level and producing 50% more than that, while at the same time restoring nature. In Pharma, it means examining illnesses that have plagued human life for as far back as memory goes and having the boldness to pursue a new treatment, and perhaps even a cure. In Consumer Health, it means providing medicines that most of us never think twice about, whether for heart health, for cuts and bruises, or for a headache, yet reaching 1 billion people with those medicines, particularly those who are most in need of healthcare. Those goals are big. They stretch across decades, but they will bring us clarity about what we are striving for, and I have confidence that we have the people, we have the products, and we have the plan to pursue them. We are focused on accomplishing that as quickly and productively as we can, and on removing everything that gets in our way...
Bill Anderson
executiveThanks a lot, and now I’ll pass things over to Wolfgang.
Wolfgang Nickl
executiveThanks, Bill. To start, I'd like to walk you quickly through the 2023 financial results. As everyone is aware, we reduced our guidance back in July of last year, largely because glyphosate prices were significantly weaker than anticipated. Thanks to a solid fourth-quarter showing—especially where cash is concerned—we met the updated targets we set out. Sales reached EUR 47.6 billion, while EBITDA before special items was EUR 11.7 billion, with both figures landing at the top end of the ranges we had given. Core earnings per share reached EUR 6.39, which likewise sits at the upper end of the guidance corridor. Under our revised outlook, we had projected EUR 0 in free cash flow for the year, yet we ended up delivering EUR 1.3 billion by year-end. That fed through into net financial debt that beat expectations as well, with the year closing at EUR 34.5 billion. Nobody could dispute that these results fall well short of the strong ones posted a year earlier. Still, it's important to remember that 2022 was an outstanding year for us, one in which unusually high glyphosate prices worked in our favor. Looking back over the last five years, our performance across that period was in fact quite robust, and we managed it within a highly volatile macro environment shaped by crises like the pandemic and the war in Ukraine.
Wolfgang Nickl
executiveAcross that five-year stretch, sales went up roughly 2% each year, while clean EBITDA rose by about 1% annually. However, those clean EBITDA figures don't carry through entirely into steady free cash flow expansion. From roughly EUR 11.9 billion of EBITDA before special items, we produced only EUR 2.3 billion in free cash flow per year on average. Naturally, CapEx, tax, financial results, and restructuring all have to be factored in, yet litigation-related payouts are another sizable driver. The latter take in settlements and judgments, plus very substantial defense costs too. Absent those items, our company would have produced roughly EUR 5 billion in cash flow per year on average. Now I'd like to spend a brief moment on how the business performed in 2023 across our three divisions, and my colleagues will walk through that in greater detail afterward. Kindly keep in mind that whenever we discuss sales growth, it is on a currency- and portfolio-adjusted basis. That holds for what I'm telling you and equally for what you'll hear from my colleagues later today. Let's begin with the agricultural business. Sales at Crop Science dropped 4% to EUR 23.3 billion. EBITDA before special items declined 27% to EUR 5 billion.
Wolfgang Nickl
executiveThe main driver here was the sharp drop in prices for glyphosate-based products. In contrast, the division posted above-market sales growth of 7% in its core business, which excludes glyphosate, driven especially by price increases. At Pharmaceuticals, sales for 2023 were level year on year, at EUR 18.1 billion. We saw significant gains from our most recently launched products, Nubeqa and Kerendia. On top of that, we continued to grow sales for EYLEA and in our radiology business. Those effects were more than offset by falling Xarelto sales and sales in China that came in much lower than anticipated. The China shortfall was due partly to pandemic-related developments at the start of the year and to an anti-corruption campaign in the health sector that indirectly weighed on demand there. EBITDA before special items at Pharmaceuticals fell by 12% to EUR 5.2 billion in 2023. That was primarily because of an unfavorable product mix and higher R&D investments. At Consumer Health, sales rose by an encouraging 6.3% to EUR 6 billion, against an already strong previous year. We posted double-digit percentage sales growth in the dermatology category, thanks partially to continued high demand for Bepanthen and Canesten, as well as in the pain and cardio category. We also increased sales of cough and cold products significantly, particularly in Europe.
Wolfgang Nickl
executiveAt Consumer Health, EBITDA before special items rose 3% to EUR 1.4 billion in 2023, driven mainly by operational productivity programs, successful price management, and sustained sales growth. With that, we more than offset the inflation-related sharp increase in costs and the higher investment in marketing innovative products. That wraps up my review of our financial figures for full year 2023. Let me now turn to the outlook for 2024, which is again adjusted for currency effects. On sales, we anticipate a relatively moderate development of -1% to +3% growth in 2024, resulting in between EUR 47 billion and EUR 49 billion. The fairly broad range we are forecasting here stems from the unpredictability of key business drivers. With respect to our top line, these are the expected double-digit decline of Xarelto sales due to the loss of exclusivity, the continued negative impact on our Pharma business in China, and the volatility of the agricultural markets. In addition, we expect increased pressure on our profitability and therefore an approximately 3%-9% decline in EBITDA before special items. This results in EUR 10.7 billion-EUR 11.3 billion. We anticipate that core earnings per share will come in between EUR 5.10 and EUR 5.50. Despite the lower profitability, we expect free cash flow to increase to between EUR 2 billion and EUR 3 billion.
Wolfgang Nickl
executiveSo our goal is to bring net financial debt down to somewhere between EUR 32.5 billion and EUR 33.5 billion. As we said two weeks ago, cutting our debt level is our clear priority over the next three years. That is mainly where our cash will go. So we intend to revise our dividend policy so that, for the next three years, we pay out only the minimum dividend required by law. For 2023, the Supervisory Board and the Board of Management will propose a dividend payment of EUR 0.11 per share at the upcoming annual shareholder meeting. I would now like to turn things over to my colleagues who run our operational businesses, and we will begin with Rodrigo in Crop Science.
Rodrigo Santos
executiveThank you, Wolfgang. It’s good to share a deeper look at how Crop Science performed. All in all, Crop Science had a solid year and delivered the revised guidance we had set after adjusting for normalization in glyphosate pricing. Excluding glyphosate — that is, our core business — growth was robust at 7%, ahead of both industry peers and the wider market. That expansion covers every region and virtually every business segment. Through world-class innovation in seeds, crop protection, and digital technologies, we are creating value for farms regardless of size, region, or crop. Consider corn, for instance, and the Preceon Smart Corn System. The breeding approach had a successful Ground Breakers program last year and is now progressing toward the target commercial introduction in the U.S. Our biotech trait approach moved to phase IV, getting closer to an estimated launch of 2027. Those are significant milestones for this promising corn system solution, which is expected to fit on 220 million acres globally. In crop protection, the launch of Fox Xpro — our newest offering for control of Asian soybean rust — will further reinforce our number one position in soybeans in Latin America. Those are just two examples of the continuous innovation we bring to farms every year.
Rodrigo Santos
executiveDuring 2023, over 400 fresh hybrids and varieties were brought to market by us, we also registered in excess of 190 novel crop protection goods, and rolled out six new formulations. Significant progress is being made in our effort to expand regenerative agriculture at scale and capture emerging market possibilities. Over in India, we rolled out our Direct Seeded Rice system, and unlike conventional rice transplant cultivation in flooded paddy fields, direct seeded rice gets sown directly into the soil. The potential exists for this approach to reduce water consumption as well as greenhouse gas emissions by over 40%. First revenue streams also came from our carbon programs, ForGround in the U.S. and ProCarbono in Brazil. Through ProCarbono Commodities, we managed to complete our initial shipments of Brazilian soybeans featuring a major tracked and deforestation-free carbon footprint. A strong illustration of what we are doing to safeguard forests and other natural vegetation. Turning to digital, the Azure Data Manager for Agriculture has officially entered preview, created under our strategic partnership with Microsoft. This platform lets companies across the agrifood value chain speed up digital innovation and generate new business value. Sitting on top of the Azure Data Manager, our AgPowered Services draw on our industry-leading know-how to deliver insights regarding crop health, weather forecast, crop growth tracking, and more.
Rodrigo Santos
executiveRegarding operations, we're making rapid progress rolling out our Dynamic Shared Ownership model — one-fifth of the 450 customer-facing plant squads have already launched and are putting changes into action. To sum up, we've posted strong results in the core business, and we keep pushing forward key technologies in our pipeline, which helps us carry out our vision of producing more, restoring more, and scaling regenerative agriculture. So with that, I'd like to turn to our outlook for 2024. On a currency- and portfolio-adjusted basis, we anticipate sales growth of -1% to +3%, with core growth of 1%-4% and an EBITDA margin before special items of 20%-22% at constant currency. Now, let me pass it to Stefan for an update on the Pharma business.
Stefan Oelrich
executiveThanks, Rodrigo. For the Pharmaceuticals division, 2023 was really a bit of a roller coaster ride. We had some remarkable achievements, though we also ran into significant challenges. So let me start by highlighting the progress we made in executing our strategy. Nubeqa, our cancer medicine, and Kerendia, our heart and kidney medicine, delivered very good results in 2023. Nubeqa sales nearly doubled, mainly driven by strong uptakes in the United States and also in Europe. With Nubeqa, we're aiming to surpass EUR 1 billion in sales this year... For our ophthalmology blockbuster product, we received approval for EYLEA 8 mg — you heard it from Bill — here in Europe, as well as in Japan in January 2024, which will allow us to secure our market leadership for the treatment of two specific types of eye diseases and provide patients with up to five months between injections. These positive developments will help us drive sales momentum and support our top line. We also made considerable progress with our late-stage development pipeline. For elinzanetant, our potential blockbuster candidate, we obtained positive top-line results in two pivotal phase III studies, reinforcing the candidate's potential as a non-hormonal treatment option, capable of transforming the way menopausal symptoms are treated.
Stefan Oelrich
executiveAs you heard yesterday, we have just bought the European marketing rights for acoramidis, which is a small molecule drug taken orally that treats a progressive and fatal heart condition. In phase III clinical trials, acoramidis met every endpoint, and European regulators are already reviewing it for marketing approval, with a launch hopefully coming next year. As part of the continuing transformation of our Pharmaceutical division, we further strengthened our research and development capabilities and sharpened our research focus onto four therapeutic areas. Those areas are oncology, cardiovascular and renal diseases, neurology and rare diseases, and immunology. Selected investments, along with the successful work of our teams at AskBio, BlueRock, and Vividion, keep strengthening our early, mid, and late-stage pipeline. We have achieved significant progress in cell therapies and gene therapies, reaching important clinical trial milestones and moving development programs forward into the next phases of clinical testing. From our chemoproteomics platform, we successfully advanced two programs into the clinic to address unmet need in cancer patients. However, some challenges also came our way. The results of a phase III study investigating asundexian in patients with atrial fibrillation at risk for stroke did not allow this specific development to continue, but we will keep investigating this important compound for secondary stroke prevention.
Stefan Oelrich
executiveThere's also another headwind, which Bill touched on: the anticipated loss of market exclusivity for Xarelto. We were feeling growing competitive pressure from generics across a number of markets. That trend is set to persist and widen into additional markets over the course of 2024. Within China, the volume-based procurement policy that's been running has weighed on our business. On top of that, the anti-corruption drive in the country's healthcare sector created indirect difficulties. We experienced an indirect adverse impact on our operations as medical events got postponed and access to healthcare practitioners stayed limited. Still, let me state this plainly: given the strong compliance culture we have, over time we will end up benefiting from a fairer and more ethical competitive environment in China. During 2024, we'll keep working through some of these challenges as well as others. Meanwhile, our new dynamic shared ownership operating model is going to help us grow more efficient and become more centered on products and customers. So we will keep investing in our Pharmaceutical business and, through that, in our future. For 2024, our forecast is a sales decline of 0%-4% and an EBITDA margin before special items of 26%-29%. Thank you for listening, and with that, I'll hand things over to Heiko.
Heiko Schipper
executiveThank you, Stefan. I'm glad to walk you through how our Consumer Health division performed in 2023 and to share a view of where we're headed in 2024 and beyond. During 2023, we delivered robust, broad-based growth of 6.3%, which came to just over EUR 6 billion, building on a very strong growth figure from the year before. That result came in above the 2023 growth guidance we had set at around 5%. We also posted an EBITDA margin of 23.4%, which is a substantial expansion of 90 basis points compared with the prior year and lands at the upper end of our full year guidance of around 23%. Delivering this against a volatile economic and geopolitical backdrop speaks to our teams, to the resilience of consumer demand, and to the ongoing appreciation and trust that consumers place in our iconic brands. The standouts were our dermatology category, which posted strong 12% growth across regions and brands, powered by Bepanthen and Canesten, along with high demand for our regional brands in China, and the 12% growth we achieved in pain and cardio. Our allergy and cold business, as well as digestive health categories, achieved strong single-digit growth in 2023, while nutritionals were on previous years' levels. Other positive developments were the strong growth of our e-commerce business, as it recorded over 20% growth and the launch of our new precision health unit.
Heiko Schipper
executiveWhen we look at the results by region, three of our four regions grew. Sales in North America came in essentially flat versus the prior year. One last thing we're proud of: in 2023, more than 75 million people in underserved communities were reached through our special access programs, and that contributed roughly 20% of our total 23% growth — which shows that widening access to proven healthcare solutions benefits our business and also serves the communities. Turning to 2024, we anticipate continued broad-based growth across our regions and categories of about 3%-6%, with an EBITDA margin of 23% to 24%, and the acceleration toward those goals really picks up after Q2. Speaking of acceleration, that's what we're doing — setting out on a bold new vision to help more than 1 billion people live healthier lives through the most trusted self-care solutions. Getting there will rest on an evolved game plan: growing our brands faster than the market and generating stronger demand among our consumers and customers for our iconic, much-loved brands. That means focusing on innovation and launch effectiveness, along with the winning creative and consumer-centric capabilities of our teams. We'll also look to speed up our operational efficiencies and our progress toward this vision by adopting new ways of working under DSO, and we've begun operating in truly cross-functional customer and category brand teams.
Heiko Schipper
executiveThe results from this approach are evident on their own, and the teams leading the way are already producing strong outcomes — among them much quicker times to market for innovative products and substantially shorter supply chain lead times. As you've already heard, I will depart from Bayer at the close of April. Looking back over the last six years, I feel enormous pride in what this team has achieved — how we turned the business around and established a genuine foundation for success. With Julio Triana, the team gains an experienced healthcare leader who has a proven record of delivery and outstanding knowledge of the company and his business, having been part of team Bayer for more than 20 years now, including time in Consumer Health. I leave with full confidence that this division, led by Julio, is well-positioned to keep delivering on its commitments and that it will pursue continued success and growth in the future with passion and drive. Thank you very much.
Bill Anderson
executiveThanks a lot, and with that, I’ll pass things over to Michael for our Q&A session.
Michael Preuss
executiveOkay, thank you very much to all of our board members for what they had to say. That said, we're going to begin the Q&A portion now. If you'd like to pose a question, here's what to do: First, please confirm that Zoom is the sole chat application running on your machine, since other software could disrupt your ability to participate. Second, please check that your microphone is enabled inside Zoom. And third, please use the raise hand feature. That way we'll note that you want to ask something, and once your turn arrives, I'll speak your name, and a pop-up window will appear on your screen. When that pop-up shows up, please unmute yourself so you can ask your question. Your camera, naturally, will stay off. So that's enough on the housekeeping side — let's begin, and let me check who has the first question. Patricia Weiss from Reuters. Patricia, the floor is yours.
Patricia Weiss
unknownGood morning, London. If I may, I have three questions. You mentioned that you intend to reduce management layers from 12 down to 5 or 6. In terms of people, could you tell us now how many jobs the cutbacks will affect? Second, you said Bayer is updating its legal strategy and pursuing new approaches, both inside and outside the courtroom, including more intensive cooperation with other players in the field of politics. What exactly does that mean? And my last question: you declared the Pharma pipeline a top priority, but you also stressed that buying phase III assets is an expensive game with a lot of risk. How do you want to strengthen the pipeline? Thank you.
Michael Preuss
executivePatricia, hearing you was quite difficult—at least for those of us in this room—so please hang on to your question for a moment while we figure out how to resolve this, since we genuinely couldn't make out what you were saying. There was considerable interference in between. Let's pause briefly. Oh, are we back? Yes? All right. So, Patricia, please keep that question on hold. We'll return to you and see whether we can sort out the technical problems we were experiencing here. Let's try Olaf Storbeck from the Financial Times first, and then, Patricia, we'll come to you after that.
Olaf Storbeck
unknownAll right, is my voice coming through?
Michael Preuss
executiveIt's hard to hear you at the moment.
Olaf Storbeck
unknownAlright, well, Patricia did a great job on the webcast, so the issue must be on your end with the acoustics.
Michael Preuss
executiveOlaf, we’re having trouble hearing you as well. Just give me — give us a second. Could they put the question in writing? Yeah, that clearly isn’t a grounding problem. That can’t be it. Something is going on with the connection. Yeah. Yeah. We’re going to get this sorted out here in the room, I hope. Just give us one second, please. But because of that, we can’t hear you. And they. Yeah? Yeah, we’re just. Give us, give us one second. We’re trying to fix it. Can we try that again?
Olaf Storbeck
unknownHello, is this coming through? Can you hear me now? It ought to be working.
Michael Preuss
executiveShould we proceed this way? Yes, hold on a moment. The team is working on it. So, apologies one time. Let's try once more. Patricia, you were up first. I realize everyone else could hear you, but we couldn't in this room. So, back to you again, and after that we'll go to Olaf Storbeck. Patricia, please begin whenever you're able to hear us.
Patricia Weiss
unknownMorning, London. Hopefully I’m coming through clearly now.
Stefan Oelrich
executiveYes, you’re coming through loud and clear now. Excellent.
Patricia Weiss
unknownApologies to everyone else for having to hear my questions once more. There are three, if I may. You mentioned wanting to reduce management layers down to five to six. When it comes to personnel, could you tell us at this point how many jobs the cutbacks will impact? Second, you said Bayer's legal strategy is being updated, with new approaches being pursued. That includes working more intensively together with other players in the political arena. What precisely does that mean? And my final question: you called the Pharma pipeline a top priority, yet you also stressed that purchasing phase three assets is a costly business carrying substantial risk. In what way do you intend to strengthen the pipeline? Thank you.
Bill Anderson
executiveThanks, Patricia. On the number of jobs, we weren’t able to provide an exact figure today, because the way we’re approaching this is fundamentally different from the typical restructuring that companies undertake. All of us have been part of these exercises before, you know, where there’s a target, such as a 10% reduction, and then everyone basically gets that target. They pull out the org chart, and they simply cut 10% of the boxes. That is not what we’re doing at all. We don’t begin with a target. We begin with, you know, a quest essentially to maximize our people’s ability on the ground to act fast, to act today to help customers, to act today to push innovation forward, and we essentially remove everything that gets in the way of that. Every step that acts as a hurdle, we remove it, and that ultimately becomes the cost-savings element of dynamic shared ownership. So we couldn’t tell you how many jobs that will be. We know it will be substantial. I think we’ve provided examples, such as in the U.S. recently in Pharma, where they removed about 40% of the management jobs, but there will be a broad range, and we’ll give more updates on that as we go.
Bill Anderson
executiveOn the legal strategy side, I think I covered that quite thoroughly in my remarks. I want to be clear that we are on this. It's a top priority. It isn't, you know, off somewhere to the side—it's front and center for us. We won't say much beyond what I just said, because we… Well, I think you'll agree, it doesn't make sense for us to hand our adversaries—the litigation industry, and it is an industry—our playbook ahead of time. So thanks for those questions. Maybe, Stefan, would you like to address whether there's a tension between saying we aren't buying phase three assets on one hand, but we do want to bolster our Pharma pipeline? How would you answer that?
Stefan Oelrich
executiveThank you. Patricia, I appreciate that really good question. This is something we've been focused on for a number of years now — how do we strengthen the pipeline in our Pharmaceuticals business? You also have to recognize that if you avoid pursuing late-stage deals that likely aren't value-adding, that's not a problem you solve overnight. So what we've been doing, and what we keep working on tirelessly, is really overhauling our whole approach to the R&D model. That means examining the capabilities we have — and you've watched us keep investing in platform capabilities and in earlier deals. More than 120 deals across the last 5 years is one piece of that. The other piece is sharpening our focus. We've made it clear that we want to concentrate on 4 areas where we see the greatest interest for us and the greatest unmet need: cardiovascular medicine and oncology, neurology and rare disease, and immunology, where we think we have distinctive capabilities matched to strong unmet need. And then there's quality. We now need to move all those early assets we've brought into our pipeline through the funnel more quickly.
Stefan Oelrich
executiveSo the goal is to take a really promising early pipeline and, over the next three years, turn it into a promising late-stage pipeline. And then let's keep in mind that when you consider how big the problem is that we're up against with the loss of exclusivity on Xarelto and EYLEA — and those are not small problems — we have significant opportunities with the products that either are launching right now or that are gearing up and getting ready for launch. So we have a number of candidates with blockbuster potential over the coming years, and with the addition of acoramidis that we added yesterday, I think we gain more credibility on our late-stage shots on goal. So all of this obviously has to continue, and we will keep making reasonable and measured investments into rather earlier deals, trying to move them forward as fast as we can. Thank you.
Michael Preuss
executiveHey, and our next question is from Olaf Storbeck. Olaf, you're up again.
Olaf Storbeck
unknownAll right, is this coming through?
Michael Preuss
executiveYes, we’ve got you loud and clear.
Olaf Storbeck
unknownOkay, so I'd like to follow up on what Patricia asked about the job reductions. You provided a figure for the savings you expect by 2026 from DSO, and that figure is EUR 2 billion. Since personnel expenses currently stand at EUR 10.7 billion, that works out to an 18% reduction. So if I'm right that roughly 18% of your workforce would have to leave — something like 15,000 to 18,000 people — would that be totally off base? Or is that roughly the ballpark you're expecting? I mean, you have to know where that EUR 2 billion is going to come from, or are these different costs rather than expenses? That's my first question, and I have two more that I'd like to ask afterward.
Bill Anderson
executiveSure, Olaf — at a high level, I'd put it this way: a lot of factors feed into this, and naturally it's also tied to the fact that these are management positions. Those roles tend to carry higher costs, and the more senior the role, the greater the expense. So you can't convert a cost-savings figure into a % of workforce. And I think our focus, again, is removing anything that stands between our people on the ground and offering a new solution to a customer today, or moving a product forward faster. When we examine that and roughly assess the various impacts it might have, we arrive at roughly EUR 2 billion. We believe we can deliver that, and yes, we're quite confident about it.
Olaf Storbeck
unknownI’ve got a cheap one too.
Michael Preuss
executiveAre there any other questions, Olaf? Perhaps you could ask them now, or we can gather them up and respond afterward.
Olaf Storbeck
unknownAlright, go ahead and ask all of them, I suppose. Otherwise it gets hard to follow with the echo and everything. So can you estimate for us what the DSO initiatives will cost each year by 2026? Then I've got a question about leverage — actually a few questions about leverage. First, you mentioned that in a potential split, the leverage for these different units would rise, at least for a while. Could you explain the reasoning there? Because the earnings flows, or the income flows, would stay the same or ought to stay the same in that scenario. That part I don't really follow. And then the other question: you said that will come down by €1 billion to €2 billion next year in 2024, if I understood that correctly. As you already — I mean, that's basically just the dividend cut, more or less, which translates into lower debt, while free cash flow is also expected to be up significantly. Why isn't the deleveraging going faster, and what else will you do with the cash?
Wolfgang Nickl
executiveOkay, Olaf, I'll begin on this one, and then other folks can add to it. That EUR 2 billion in savings will clearly come with one-time costs. Compared with earlier programs, those costs are going to be smaller as a proportion of the savings. You likely remember we consistently referenced 1.5x-0.7x. This time around, you'll find it nearer to 1x. That's mostly down to how the actions are composed. Let me tackle the debt first. Moving toward a single A/A rating is our number one priority. That's very clear. I think the dividend cut also made that clear. Good question about why free cash flow doesn't carry all the way through to net financial debt, and the simple reason is that certain items sit between free cash flow and the total change in cash. For example, milestone payments still outstanding from M&A action we carried out in the past. It could be certain pension provisions. It is indeed the dividend you brought up, and we've also provisioned for some additional effects, with fluctuation there too. So we'll clearly try to optimize that figure, but those are really the main items feeding into it.
Wolfgang Nickl
executiveFinally, and this is not the least important point, as Bill said, a spin or an IPO involves numerous considerations, and time to money is among them, correct? With an IPO, if things go well, it takes 2 or 3 years before the shares are sold. During that period, though, you are building up substantial costs. There is the one-time expense of rewiring the systems, and there is possible tax leakage you might face depending on how the transaction is structured. All of that will push your costs higher, drive profitability lower, and increase leverage. Also keep in mind that selling a business means you are handing over that business's profit as well, and that too will affect leverage. So I hope this gives you some useful pointers for your questions.
Michael Preuss
executiveThanks. Our next question is from Ludwig Burger at Reuters. Ludwig, the floor is yours.
Ludwig Burger
unknownMuch appreciated, and good morning to everyone. If I could, I'd like to direct a question to Bill regarding the dividend-related items you flagged in your release, where you indicated that you'd held discussions with shareholders, and that as of today you've decided to set aside certain specific actions concerning the structure. I'm curious about your read on how shareholders will react, since some of them have asked — indeed, strongly pressed — for a reconsideration or a review of how the company is structured, and especially now that Jeffrey Ubben is set to join the Supervisory Board. I'm genuinely eager to know: how are things going between the two of you? What are Jeffrey Ubben's views? What does he contribute? Will he be pleased that you're dropping the restructuring steps, the group structure changes, or the buyback of up to three years? Thank you.
Bill Anderson
executiveOkay, Ludwig, I appreciate the questions. So yes, on this choice to hold off on any kind of structural moves, at least for the coming two to three years — we've been able to have a great many conversations with major shareholders, honestly, throughout my entire tenure at the company. It's evident there have been plenty of requests for a breakup, for the reasons I laid out — you know, a pure-play structure is simple. The majority of our competitors are pure-play. Yet our major shareholders likewise grasp the nitty-gritty of corporate breakups, and they grasp that one-time costs exist, they grasp that there is considerable tax leakage, and they grasp that the current valuation environment isn't particularly favorable. So I believe what we've mostly heard from them is, "Hey, we, we need to do what's best for the company in the long term." And I, I believe that they, they grasp that the four topics I've mentioned, these four challenges, are, are things we need to address, and that the time required for, you know, some kind of major financial structure change is, is time we can't afford and, to lose in addressing those, those topics.
Bill Anderson
executiveOn the subject of Jeffrey Ubben, I won't claim to represent his views. That isn't my role. What I can tell you is that he has served as a productive member of a number of boards. I've had the chance to speak with CEOs at other companies who have worked alongside him over the years. I believe shareholders regard him as someone who advocates very squarely for what's best for the shareholders. And I think management knows him as someone who is highly intelligent and focused on truly adding value and on how companies add value. So I look forward — and I think all of us do — to having his input from our Supervisory Board, along with that of the other new and existing members.
Michael Preuss
executiveAlright, our next question is from Jonas Jansen at Frankfurter Allgemeine Zeitung. Jonas, the floor is yours.
Jonas Jansen
unknownHello, and thanks. Thank you, and good morning. I'd like to ask whether you could tell us a bit more about the glyphosate plans — not the legal side, but rather the financials, since it had a big impact over the last year. What are your plans for glyphosate going forward? And then, perhaps, moving to the legal part, how large a role will glyphosate play in the coming years for Bayer?
Rodrigo Santos
executiveLet me address that. We'll be sharing more details later this afternoon, but the basic picture is this: with glyphosate, 2022 was an exceptional year, and at this point we've returned to a normal situation for glyphosate. That's also the basis for how we're guiding for the future, including next year. For the coming 2024 season, our guidance essentially relies on the 15-year average glyphosate price, which lets us keep our real focus on the core business. Everything innovative we bring sits within the core, and that's why we reinforced last year's performance — 7% growth on the core business. For 2024 we're planning further growth, and the foundation for that is our innovation, our new launches in seeds and traits and in CP, and digital technology. So we treat glyphosate as a more volatile business, guiding on the 15 years, while staying highly focused on the core business and on how we deliver that innovation to the farmers. Thank you for your question.
Bill Anderson
executiveAnd I might just add that, regarding future plans, Bayer is — as many of you know, I think — the largest investor in R&D for agriculture, for the future of feeding the world and making sure we can do it in a way that's also good for the planet. And glyphosate today is a big part of that for the world. That's not Bayer's call. That's basically what farmers tell us — that it's indispensable for allowing them to produce food at an affordable price for consumers in the developed world and in the emerging markets. So that's the situation today. Going forward, we're investing in a number of new herbicide projects. We are looking forward, I think, in 2028 to bringing to the world the next fundamentally new category of molecules as a herbicide. This is something that's really important because weeds, fungi, insects, they all evolve, and if you just keep using the same protection products over time, they're gonna break through, and you're gonna have problems. So we look forward to a future of all the things Rodrigo said, that we're gonna deliver, agriculture for the world, food for the world, and we wanna do that with better products.
Michael Preuss
executiveAnd then we’ll go to Aimee Donnellan at Reuters. Aimee, the floor is yours.
Aimee Donnellan
analystHello there. Is my audio coming through clearly for you?
Michael Preuss
executiveYes, we’re able to hear you.
Aimee Donnellan
analystRight, thanks. I just wanted to ask about — you know, you laid out the reasons selling the consumer business doesn't make sense, and one of those reasons involves tax leakage and additional costs. Could you maybe walk us through a bit what exactly that tax leakage is, and what those additional costs consist of?
Bill Anderson
executiveOkay, I'll just keep this straightforward, and if there's anything more—so the tax leakage piece is fairly straightforward. On a company's balance sheet, you carry a value for the assets. So we carry a value for the Consumer Health assets on our balance sheet. Those are, you know, by product or, in certain cases, entire business lines. And basically, if you sell something above what it's worth, then tax authorities across various jurisdictions say, "Hey, that — you just made a profit because, you know, the value on your books is EUR 1 billion, and you sold it for EUR 5 billion, so you made EUR 4 billion in profit. So, you need to write us a check for 30% of that," and 30% of that is EUR 1.2 billion. So in that example, you know, you have EUR 5 billion of cash coming in, but you got to write a check for EUR 1.2 billion. And where we're standing right now, the idea of writing checks to governments for selling things is not very appealing. So I think that's sort of the simple answer on the tax leakage. Extra cost is just, you know, right now we have one finance system for all of Bayer.
Bill Anderson
executiveAll of Bayer operates with a single payroll department. Splitting would mean we'd need finance systems that are separate, payroll systems that are separate, and that carries costs. So those are the types of costs we're referring to.
Aimee Donnellan
analystMind if I ask a quick follow-up on that? Since you're referring to the thing you're discussing.
Michael Preuss
executiveTim Loh from Bloomberg is up next. Tim, the floor is yours.
Tim Loh
unknownHi, thanks. Yeah, Bill, the answer you gave to that last question sort of leads right into something I had in mind, and I've got two here. First, I'll just ask: throughout, one thing I've been wondering is whether, implicitly in this review, you've been saying that Pharma is core to Bayer, because you've talked about the possibility of selling off Consumer Health or doing something with crops, but I haven't heard anything about — I don't think there was ever a possibility of selling off Pharma and keeping the other two. So that's question one: Is Pharma in some way more core to Bayer than the others? The second question is, you just discussed some of the reasons why now isn't the time to engage in this split, and possibly for the next 24 to 36 months. If you were to decide in 2 years' time or 3 years' time that you do want to sell off Consumer Health or do something with crops, does that start the clock at, you know, at that point, and then you have to go through all of these steps that you're not wanting to do right now? In which case, some sort of a separation is potentially 4 or 5 years away, or are you gonna start doing preparatory work now so that should you decide to sell off one of those pieces, you can do it very fast?
Bill Anderson
executiveAn IPO for Pharma — is that happening because Pharma is considered core? I'm not sure. "Core" can be somewhat of a feeling, and naturally, we love our Pharma business. We love being involved in, you know, delivering solutions globally for cancer, Parkinson's disease, and heart disease. That said, that isn't really the, you know, reason we didn't look at spinning off Pharma or selling Pharma. Basically, it's simply that at present there's a great deal of uncertainty surrounding the, you know, Pharma outlook given the patent expirations, and so it likely wouldn't be a very wise moment to attempt a spin or attempt an IPO. And in the same way, you know, I don't believe this would be a favorable time from a valuation standpoint. So we essentially removed that from consideration, and honestly, I don't believe any of our investors have shown any appetite for that option either. As for the other question of, you know, if not now, if we were to pursue one of these structural moves in two to three years, does that mean the clock resets? I think at this moment, as I mentioned, we're truly concentrated on these four things.
Bill Anderson
executiveIf we're able to address those four items, that provides us with strategic flexibility. To answer your question directly about whether the prep work begins now: not really, beyond the fact that we're getting all of our businesses ready for a stronger future. I mention that because, in the example I gave about having separate payroll systems, we aren't going to begin building separate payroll systems. At this moment, that would be an unproductive activity, and right now is a period when unproductive activities are something we can't afford. Everything has to stay focused on customers and product innovation. So I'm confident that if, in 2 to 3 years' time, we conclude a structural move is the right answer, we'll be able to carry that out in an expeditious manner. Thanks, Tim.
Michael Preuss
executiveAlright, Aimee, I believe you had a follow-up question that we weren't able to hear in the room, but I'd like to give you the chance to ask it. So once more, to Aimee from Reuters. Aimee, can you hear us? Let's give it another try. If not, we can come back to you later in the queue, which is also an option.
Aimee Donnellan
analystAlright, I believe I'm connected at this point. Is my audio coming through clearly?
Michael Preuss
executivePerhaps we should just proceed, and then, Aimee, we'll return to you afterward. Following that, Stephen Wilmot from the Wall Street Journal is next. So, Stephen, the floor is yours.
Stephen Wilmot
unknownHello everyone. Is my audio coming through okay?
Michael Preuss
executiveYeah, we can hear you.
Stephen Wilmot
unknownAlright, three questions from me. First, in your guidance you mention lower EBITDA and higher free cash flow — could you explain what changes on the cash conversion side? Second, you say the current valuation environment isn't favorable for a Consumer Health sale, but it doesn't look that bad to me. There have been reports of interest in the Sanofi Consumer Health business, and Haleon's share price hasn't been a disaster. I'm just not entirely sure what I'm seeing — what do you mean by the environment not being favorable? So maybe you could clarify that. And also — you said the Supervisory Board is preparing a new incentive scheme, with the short-term focus on revenue growth, profitability, and cash, and the longer term more aligned with shareholder outcomes. Could you be a bit more specific about what that means? I mean, obviously with the share price at a 20-year low, it would be obvious to have a bigger focus on the share price as part of that, but I just wanted to understand what's in store there. Though I appreciate you're not the Supervisory Board.
Wolfgang Nickl
executiveThis is Wolfgang. I'll handle the first question, and then Bill will, I believe, cover the remaining two. Good catch on that. Yes, profitability is declining at both the EBITDA and EPS levels is rising. I'd highlight three main factors. First, although we aren't explicitly stating it, we anticipate fewer settlements in 2024 than what we disbursed during 2023. A second factor involves how the timing of STI payouts, or short-term incentive payouts, in the subsequent year affects cash flow. So picture this: during 2023, we paid out incentive entitlements for 2022, a year that was very strong, while in 2024 we're paying for 2023, which was very weak. That's where you see the difference. And of course, we're placing heavy emphasis on managing working capital and CapEx. We could dive into each area — inventory, AP, AR — we'll tackle all of it, and we anticipate improvement there too, which clearly helps leverage cash flow relative to profitability. Bill?
Bill Anderson
executiveYes. And Stephen, on what you asked about valuations — why we believe Consumer Health valuations aren't really optimal at the moment — I think you just need to take a straightforward look at a few facts. There are two Consumer Health businesses that are the biggest, and both sit inside other companies, with Bayer being one of them. There have been talks about separating them, or making them separate, going on for a number of years now, and you still haven't seen that take place. And when valuations are high, normally an acquirer comes knocking and puts the money down. And that kind of hasn't happened yet, right? So I think we have plenty of conversations with investment bankers and with other industry leaders, and that's essentially how the land lies. On the LTI alignment question, to put it simply, the LTI structure senior managers have today puts 20% on ESG measures, 40% that is essentially linked to the share price, and 40% tied to a measure known as return on capital employed, which is a financial metric. And the fact is that financial metric is highly exposed to things such as changes in the valuation of intangibles on the balance sheet.
Bill Anderson
executiveSo that means it might rise during a year in which the share price falls, and it might fall in a year when the share price rises. This happens for a range of idiosyncratic reasons, and it isn't especially aligned with shareholders' interests, whether you look at it in one-year increments or, in certain cases, over a longer horizon. Therefore, what the Supervisory Board recommends is that rather than the 20, 40, 40 split, where 40% is tied directly to the share price, we move to 20% on ESG and 80% aligned with the share price. I hope that makes it clear for you, Stephen.
Michael Preuss
executiveAnd our next question is from Kevin Grogan at Scrip. Kevin, the floor is yours.
Kevin Grogan
unknownGood morning, everybody. Is my voice coming through okay?
Michael Preuss
executiveYeah.
Kevin Grogan
unknownGreat. Yeah, just a quick one — really a couple of questions on Pharma. Bill, you mentioned — and this goes back to Tricia's point again — that buying Phase III assets is a costly business with a lot of risk. Yet you've just closed the BridgeBio deal. A very interesting deal, I'd say. So should we be looking for more licensing deals in certain areas, maybe, instead of acquiring products? Because the late-stage pipeline still looks somewhat thin, given that perhaps the only filing coming soon now will be elinzanetant in the near future. And just one more for Stefan as well. Could you elaborate a bit on the issues in China that you referred to and the indirect challenges stemming from the country's anti-corruption campaign? How long do you think it will take before things in China recover for Bayer? Thank you.
Bill Anderson
executiveAlright, I'll keep this brief to start, and if there's more to cover, we can bring in Stefan, since he brings a great deal of experience on this topic. In my view, BridgeBio stands as an illustration of a deal where both sides come out ahead. It works well for them since they're a smaller company just ramping up with their first launch, and they're able to concentrate their efforts on the U.S. At the same time, we've got a sizable sales force and an established presence in cardiovascular health across Europe, and this fits neatly into that. And it's a deal, you know, that we secured on sensible terms. The risk isn't high given that the clinical data is already in hand, so it benefits us and benefits them too. I'd say yes, we're always willing to consider deals of that kind, and as Stefan noted, we've completed more than 100 licensing deals over recent years, and you should expect that to keep going. On the question regarding the anti-corruption campaign in China, it basically had an impact across the entire healthcare sector and lowered demand for healthcare broadly. That's the reason we describe it as an indirect effect — we weren't involved or implicated in the actual investigations, but it simply impacts overall business for many companies in China, and since a relatively large share of our business sits in China, we felt it more than some others did.
Bill Anderson
executiveWell, thank you.
Michael Preuss
executiveAlright, so moving on to Aimee. We gave it another shot — I realize you called back in, and there's a follow-up you'd like to ask — so Aimee, the floor is yours. Let's see whether we can get you connected at this point.
Aimee Donnellan
analystHi again — sorry about that. Can you hear me at this point?
Michael Preuss
executiveCan you hear us? Yes, we’re able to hear you.
Aimee Donnellan
analystYeah. Okay, great. You know, I just wanted to follow up on the question. I think I basically got cut off. But regarding the consumer bit, the reason I was asking about selling the consumer business and why you might do that, and I understand, obviously, the tax implications. But if you're thinking about your business and thinking about your debt levels, the U.S. litigation, this would be a way of raising some money to pay down debt, to put money into your drugs pipeline. And if ultimately, your plan is to break up the business in the future, I'm not saying it is, but if it is, then why not do it now? And I think I heard one of my peers talk about the fact that there is obviously a number of other, you know, businesses out there. There's... There is going to be Sanofi's consumer business, there is Haleon, and there is talk of a lot of private equity interest in these businesses. So I'm just kind of curious as to why that timing wouldn't be right. And then I have just one other question about the U.S. litigation. Somebody was mentioning to me that it might be better, this might be maybe pie in the sky, but if you could deal with maybe a large law firm that might pool some of these cases together, and therefore, you wouldn't be having such regular court cases, and the headlines and all of that that's associated with that.
Aimee Donnellan
analystAnd I was wondering whether that's a topic you folks have been considering or talking over.
Bill Anderson
executiveYeah. So, Aimee, thanks for those questions. Yeah, regarding the question of, you know, why not sell Consumer Health, I mean, I addressed most of that area. The simple fact is, we feel pretty good about our ability to fund the kind of rejuvenation in our Pharma pipeline that we believe is value-added for shareholders. In other words, we don't have, you know, $10 billion extra dollars to go make a phase III purchase or a you know ready-to-launch purchase... But we do have the funding to fund you know the 13 INDs that we got approved in the last two years to do deals like the one that Stefan mentioned with BridgeBio and many others.
Aimee Donnellan
analystCould I just — is it possible to ask a quick follow-up about your sponsor?
Michael Preuss
executiveAnd our following question is from Rayna.
Analyst
analystRegarding the DSO changes, you mentioned earlier that you want to get the most out of your German footprint in Pharma R&D. So does that mean Pharma R&D is going to be centered in Germany going forward? And my second question: you said cardiovascular would be one of your focus areas. Would that also cover metabolic diseases, perhaps including obesity?
Stefan Oelrich
executiveI want to be completely clear on this. You're correct that historically our R&D presence has been quite robust in Germany. That said, when you consider the acquisitions we've made during the past 5 years, that presence has grown considerably — particularly given our emphasis on the U.S. So we will see... But for us, that would be a long shot.
Bill Anderson
executiveI might just make one more remark here, since I'm still fairly new to this. As Stefan said, we've got a genuinely strong balance on the innovation front between the U.S. and Germany. But what I suspect gets little attention is just how excellent a location Germany is for drug development — and I'm drawing a distinction there with research. So innovation is taking place on both sides of the Atlantic, yet Germany is in fact a very effective spot for, you know, the blocking and tackling work that drug development involves, which is, you know, running clinical trials, statistics, process development for new products. Every one of those is an area where the cost base in Germany sits substantially lower than the key centers of Pharmaceuticals and biotechnology, for example, in the U.S. We have a substantial cost base, and we have excellent talent, you know, highly qualified scientists, doctors, statisticians. So I think that's one of the ways that Stefan and Christian Rommel and their team are able to drive so much innovation on so many molecules with, you know, a relatively modest R&D budget. And, yeah, I wouldn't change that for, yeah, at all.
Stefan Oelrich
executiveOur Italian Pharma organization is serving as the pacesetter for rolling out DSO, and that effort is already generating a great deal of momentum—and freeing up even more momentum—when it comes to how we respond to what customers need in Italy. Beyond that, Italy will, of course, remain a significant channel for delivering new medicines to patients. And I feel solid confidence that, with the present administration, we can also secure strong access for patients to those innovations in Italy. Many thanks.
Wolfgang Nickl
executiveWolfgang here — I can probably jump in quickly on the AI topic and cover it for the whole company, then my colleagues can add to that. It's hugely important. Some researchers, I believe, place it in the same category as the invention of the steam engine or the World Wide Web. So we're seeing it across the entire company. You'd find it in the divisions, whether that's in silico development, improving our marketing, or digital farming. My colleagues could go into more detail on that, and also on the corporate side. I mean, think of expert systems in legal, for example, or our global business services doing a much better job of providing services to our employees, our suppliers, and our customers. So yes, artificial intelligence is a focus for us everywhere in the company.
Bill Anderson
executiveSure. I’ll give you one anecdote, since this shows where AI is heading. By the way, someone recently proposed to me that perhaps we ought to bring in a head of AI and set up an AI department. You can picture that, as our new system, Dynamic Shared Ownership, is about really placing power with the people doing the work, we aren’t very keen on setting up new central functions with new heads of things. I told them that would be like a company in 1990 bringing in a head of personal computers, you know? Because that’s what—that’s how AI is spreading right now. To give you one concrete illustration of that: so we have a new system for running the company, and it’s very different from what companies typically have done in the past and what Bayer’s done in the past. So we have 100,000 people at our company with questions about Dynamic Shared Ownership. You know, what does that mean for career? What does that mean for promotions? What does that mean for this and that? And so last week, a couple employees sent me a link to a new AI chatbot that they created in their spare time to answer employees’ questions about Dynamic Shared Ownership.
Bill Anderson
executiveSo, I mean, they apparently came across a lot of the stuff we'd discussed — things I'd used, YouTube videos, various sources. In their free time, they built a chatbot. So I decided to test it out, and I posed 5 or 6 of the questions I hear most often, just out of curiosity — like, "Hmm, how would those answers stack up against what I'd have said?" And I have to tell you, 5 of the responses were pretty solid, and 1 was fine. But that's how AI is spreading. So when you hear leaders claim, "Oh, yeah, we're on top of AI, and we've got it all sorted out," don't buy it. AI is taking place all around us, and the crucial question is: how do we unlock our people's capacity to take advantage of these new tools and do their jobs better and faster?
Michael Preuss
executiveAll right, and now there's a last question — we'll take follow-ups from Tim Loh at Bloomberg. Tim, the final question is yours.
Tim Loh
unknownHello, and thank you. You largely addressed the earlier question regarding litigation in the U.S., so I thought I would give it a try as well. You have spoken about being open, and your team is, as you know, weighing every possibility. One of the concepts that has come up, including from Jeffrey Ubben roughly a year ago, is what people call the Texas Two-Step, which is something J&J has been pursuing, with talc and so forth. It is fairly controversial. The Supreme Court has offered some views on it. But apart from that, I have not really heard of many alternatives that would help sort of bring all of these claims together. And I am curious: do you think Bayer would be open to looking at that, or do you consider it too extreme?
Bill Anderson
executiveHonestly, there isn’t a great deal more I’m able to add here. We’re actively on it, and we will look at every sensible avenue for safeguarding the company and safeguarding our mission against the litigation industry. So, we’re not. I believe you’d agree that revealing our plans ahead of time wouldn’t serve our best interests. So expect additional steps from us over the coming months, though you won’t necessarily hear about them in advance. Thank you.
Michael Preuss
executiveOkay, that's all from us. Thanks a great deal — really appreciate your questions. Thanks so much… We'd like to wish each of you a really good day. Take care, keep well, and goodbye.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.